Related Experiment Videos
Budesonide once versus twice-daily administration: meta-analysis
Matthew Masoli1, Mark Weatherall, Shaun Holt
1Medical Research Institute of New Zealand, Wellington, New Zealand.
Respirology (Carlton, Vic.)
|December 23, 2004
Summary
For mild to moderate asthma, once-daily budesonide is as effective as twice-daily dosing. This asthma treatment offers potential benefits for patient compliance and satisfaction.
Area of Science:
- Pulmonology
- Pharmacology
Background:
- Asthma management often involves inhaled corticosteroids.
- Budesonide is a commonly prescribed corticosteroid for asthma.
- Dosing frequency can impact treatment adherence and effectiveness.
Purpose of the Study:
- To compare the efficacy of once-daily versus twice-daily budesonide in asthma patients.
- To evaluate clinical outcomes associated with different budesonide dosing frequencies.
Main Methods:
- A meta-analysis of randomized controlled trials was performed.
- Included studies compared once-daily versus twice-daily budesonide administration.
- Clinical outcome measures and withdrawal rates due to asthma were analyzed.
Main Results:
- 10 studies with 1922 participants (children and adults) were included.
- No significant difference in efficacy was found between once-daily and twice-daily budesonide.
- Withdrawal rates due to asthma were similar for both dosing regimens (OR 1.0, 95% CI 0.65-1.52).
Conclusions:
- Once-daily budesonide is as effective as twice-daily dosing for mild to moderate asthma up to 800 microg/day.
- A once-daily regimen may improve patient compliance and satisfaction.
- This suggests a simpler dosing schedule may be a viable option in clinical practice.